Drug Development

Articles

EMA has fully validated the marketing authorization application for Atara Biotherapeutics’ off-the-shelf allogeneic T-cell therapy, tab-cel (tabelecleucel), with an approval decision expected in 2022.

Atara Biotherapeutics' MAA for Allogeneic T-cell Immunotherapy Gets EMA Validation

Chinook Therapeutics has formed a 50/50 joint venture with investors to develop kidney disease therapies in China.

Chinook Therapeutics and Investors Form Joint Venture for Kidney Disease Therapies

BeiGene has acquired property in Hopewell, NJ to build a new manufacturing site and clinical R&D center for advanced new medicines.

BeiGene Acquires Property in New Jersey to Build Manufacturing and Clinical R&D Center

Samsung Biologics, GreenLight Biosciences, and Environmental Impact Acquisition Corp. have partnered to advance GreenLight’s mRNA COVID-19 vaccine candidate.

Samsung Biologics, GreenLight Biosciences, and Environmental Impact Acquisition Corp to Build mRNA Vaccine Manufacturing Capacity

Secarna Pharmaceuticals and Achilles Therapeutics have entered into an agreement to optimize the development of T cell therapies in Achilles’ pipeline.

Secarna Pharmaceuticals and Achilles Therapeutics Partner on T Cell Therapy Development

CGT Catapult and Deep Science Ventures have partnered to encourage innovative approaches to overcoming barriers in delivering advance therapies to patients.

CGT Catapult and Deep Science Ventures Team Up to Boost Innovation in Advanced Therapies

Under the expanded agreement with Agios, Centogene will provide global clinical trial support for thalassemia and sickle cell diseases.

Centogene Expands Rare Blood Disease Partnership with Agios

Jennifer Markarian is manufacturing reporter for Pharmaceutical Technology.

Gernot Warnke, Head of R&D, JRS Pharma, spoke about excipients and how these relate to feeding in batch and continuous manufacturing. 

Equipment Trends in Advanced Solid-Dosage Drug Manufacturing: INTERPHEX Keynote Part 5

Feliza Mirasol is the science editor for 

Chris Spivey is director of Industry Relations and Strategic Partnership, MJH Life Sciences.

Part 2—Industry experts from MilliporeSigma, Lonza, Astrea Bioseparations, and Sartorius provide insight and examples about solving critical challenges in both analytics and process development for emerging therapies.

Advances in Molecule Characterization and Biomanufacturing for Emerging Therapies: Part 2

Part 1—Industry experts from MilliporeSigma, Lonza, Astrea Bioseparations, and Sartorius discuss key issues affecting the development of emerging biotherapies.

APIs and Excipients